Search research articles
Contact Us
Filters
Showing results (321-330 of 451) with videos related to
Page
of 46
Sort By:
Antiviral Therapy
|
November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Jordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
Canadian Liver Journal
|
August 22, 2022
Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study
Brian Conway, Julie Bruneau, Curtis Cooper, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 6, 2023
Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings
William W L Wong, Josephine Wong, Karen E Bremner, et al.
Science Advances
|
May 29, 2026
Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models
Seung Bum Park, Jaime Sánchez-Meza, Regina Umarova, et al.
Journal of Viral Hepatitis
|
October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection
Julia L Casey, Gregory J Dore, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 13, 2024
Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study
Rachel L Epstein, Sarah Munroe, Lynn E Taylor, et al.
Hepatology (Baltimore, Md.)
|
December 15, 2018
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection
Jordan J Feld, Norah A Terrault, Hsing-Hua S Lin, et al.
Gastroenterology
|
January 20, 2026
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial
Grishma Hirode, Hooman F Zangneh, Orlando Cerocchi, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
Y Rotman, B B Borg, A Soza, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 24, 2018
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis
Hooman Farhang Zangneh, William W L Wong, Beate Sander, et al.
Page
of 46
Search research articles
Search
Showing results (321-330 of 451) with videos related to
Sort By:
Page
of 46
Antiviral Therapy
|
November 16, 2022
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Jordan J Feld, Eric Lawitz, Tuan Nguyen, et al.
Canadian Liver Journal
|
August 22, 2022
Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study
Brian Conway, Julie Bruneau, Curtis Cooper, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
January 6, 2023
Impact of direct-acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings
William W L Wong, Josephine Wong, Karen E Bremner, et al.
Science Advances
|
May 29, 2026
Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models
Seung Bum Park, Jaime Sánchez-Meza, Regina Umarova, et al.
Journal of Viral Hepatitis
|
October 27, 2022
Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection
Julia L Casey, Gregory J Dore, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 13, 2024
Clinical- and Cost-Effectiveness of Liver Disease Staging in Hepatitis C Virus Infection: A Microsimulation Study
Rachel L Epstein, Sarah Munroe, Lynn E Taylor, et al.
Hepatology (Baltimore, Md.)
|
December 15, 2018
Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection
Jordan J Feld, Norah A Terrault, Hsing-Hua S Lin, et al.
Gastroenterology
|
January 20, 2026
Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial
Grishma Hirode, Hooman F Zangneh, Orlando Cerocchi, et al.
Alimentary Pharmacology & Therapeutics
|
February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response
Y Rotman, B B Borg, A Soza, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
December 24, 2018
Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis
Hooman Farhang Zangneh, William W L Wong, Beate Sander, et al.
Page
of 46